Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial

Trial Profile

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Sponsors BIAL - Portela C S.A.
  • Most Recent Events

    • 27 Apr 2018 Results (n=418) of a pooled analysis assessing predictors of response to placebo from 093-301, -302, and -304 studies, presented at the 70th Annual Meeting of the American Academy of Neurology
    • 27 Apr 2018 Results of analysis evaluating changes in sodium and thyroid hormone levels during treatment with adjunctive ESL using patient data pooled from BIA-2093-301, -302 and -304 trials presented at the 70th Annual Meeting of the American Academy of Neurology
    • 05 Dec 2017 Results of pooled post hoc analysis from three phase III trials (BIA-2093-301, -302 and -304), presented at the 71st Annual Meeting of the American Epilepsy Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top